Genomic Health, Inc.
Genomic Health, Inc. is the leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimise cancer treatment decisions. For more information, please visit, www.GenomicHealth.com or www.oncotypedx.com
The four commercial products include:
- The Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive ER+, HER2- breast cancer.
- The Oncotype DX® breast cancer test for DCIS predicts the likelihood of recurrence.
- The Oncotype DX® colon cancer test, the first multi-Gene expression test developed for the assessment of risk of recurrence in patients with stage II or III disease.
- The Oncotype DX® prostate cancer test identifies low- to intermediate-risk patients eligible for active surveillance, as well as those who may benefit from immediate invasive treatment by predicting disease aggressiveness.
ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.
The aim of this review is to evaluate the incorporation of genomic testing in international guidelines (North American and European) in different clinical settings.
At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincent’s University Hospital, Dublin, Ireland, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx).